The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms
Open Access
- 8 November 2004
- Vol. 101 (12) , 2802-2808
- https://doi.org/10.1002/cncr.20716
Abstract
BACKGROUND Exogenous reactive oxygen species (ROS) induces DNA damage. Manganese superoxide dismutase (SOD2) catalyzes the dismutation of superoxide radicals, a major type of ROS, into hydrogen peroxide. p53 is a tumor suppressor gene, and X-ray cross-complementing group 1 (XRCC1) is involved in the base-excision repair of ROS-induced DNA damage. METHODS The authors investigated whether the SOD2 Ala16Val polymorphism modifies the associations between p53 Arg72Pro and XRCC1 Arg399Gln polymorphisms and the risk of nonsmall cell lung carcinoma (NSCLC) in a case–control study of 935 Caucasian patients with NSCLC and 1233 healthy control participants. The results were analyzed using logistic regression models that were adjusted for possible confounding variables. RESULTS There was no association between p53 or XRCC1 polymorphism and NSCLC risk for individuals with SOD2 Ala/Ala or Ala/Val genotype. For individuals with the SOD2 Val/Val genotype, greater risks were found in association with p53 (variant Pro allele vs. Arg/Arg), XRCC1 (variant Gln allele vs. Arg/Arg), and the combination of the two polymorphisms (“double variant” vs. “double wild type”), with the adjusted odds ratios (ORs) of 1.84 (95% confidence interval [95% CI], 1.20–2.82), 1.39 (95% CI, 0.98–2.21), and 2.54 (95% CI, 1.38–4.68), respectively. Furthermore, the greater risk for the double variant of p53 and XRCC1 in the SOD2 Val/Val genotype group was specific only for patients with adenocarcinoma and not for patients with squamous cell carcinoma, with adjusted ORs of 3.31 (95% CI, 1.68–6.51) and 0.69 (95% CI, 0.24–2.02), respectively. CONCLUSIONS The SOD2 Val/Val genotype may increase the risk of NSCLC carried by XRCC1 and p53 polymorphisms, particularly for adenocarcinoma. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer modelOncogene, 2002
- Genes regulated in human breast cancer cells overexpressing manganese-containing superoxide dismutaseFree Radical Biology & Medicine, 2001
- Oxyradicals and DNA damageCarcinogenesis: Integrative Cancer Research, 2000
- The role of manganese superoxide dismutase in health and diseaseJournal of Inherited Metabolic Disease, 1998
- Transfection and Expression of MnSOD cDNA Decreases Tumor Malignancy of Human Oral Squamous Carcinoma SCC-25 CellsHuman Gene Therapy, 1997
- Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutaseOncogene, 1997
- Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells.Proceedings of the National Academy of Sciences, 1993
- Tumor Suppressor GenesScience, 1991
- Free radicals, antioxidant enzymes, and carcinogenesisFree Radical Biology & Medicine, 1990
- Mitochondrial mutations may increase oxidative stress: Implications for carcinogenesis and aging?Free Radical Biology & Medicine, 1990